Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
David Ruiz-Guillamon
Observed names:
David Ruiz Guillamón,
David Ruiz-Guillamón
Institutions:
Navarre Institute of Health Research,
Clinica Universidad de Navarra,
Centro de Investigación Médica Aplicada
Observed institutions:
Navarre Institute of Health Research,
Clinica Universidad de Navarra,
Centro de Investigación Médica Aplicada,
Universidad de Navarra
ORCID:
0009-0001-5327-4449
Observed ORCID:
0009-0001-5327-4449
OpenAlex ID:
A5107436828
Non-mitogenic FGF19 mRNA-based therapy for the treatment of experimental metabolic dysfunction-associated steatotic liver disease (MASLD)
2024
·
Amaya Lopez-Pascual
, Joan S. Russo-Cabrera
, et al.
·
Clinical Science
·
15
Intratumoral administration of Hibiscus sabdariffa-derived anthocyanins exerts potent antitumor effects in murine cancer models
2025
·
Miriam Ezcurra-Hualde
, Juan Florencio Gómez-Leyva
, et al.
·
Frontiers in Immunology
·
6
Liposomal encapsulation of cholecalciferol mitigates in vivo toxicity and delays tumor growth
2025
·
Miriam Ezcurra-Hualde
, Sara Zalba
, et al.
·
Frontiers in Immunology
·
6
PDF
Conventional type-1 DC density is associated with checkpoint inhibitor response across multiple types of cancer
2026
·
Alvaro Lopez-Janeiro
, José González-Gomariz
, et al.
·
Journal of Clinical Investigation
·
5
PDF
Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026
·
Miguel F. Sanmamed
, Carlos E. de Andrea
, et al.
·
Clinical Cancer Research
·
5
TNFR1 expression on cancer cells mediates immune escape and an immunosuppressive microenvironment
2026
·
Elixabet Bolaños
, Lorena Cañas-Zabala
, et al.
·
The Journal of Experimental Medicine
·
1
PDF
Autocrine activity of engineered IL-33 mRNA enhances adoptive T-cell therapy for peritoneal carcinomatosis and synergizes with IL-12 mRNA
2026
·
Leire Arrizabalaga
, Claudia Augusta Di Trani
, et al.
·
Theranostics
·
1
PDF
Comprehensive Spatial Methods (CSM): a Toolbox for Spatially Analyzing Tissues in Histopathology
2025
·
Alvaro Lopez-Janeiro
, Eduardo Miraval-Wong
, et al.
·
Laboratory Investigation
·
1
A stabilized abdominal imaging platform for intravital interrogation of preclinical omental metastatic niche models
2026
·
Román García-Fuentes
, Nicolás López de Aguileta
, et al.
·
Scientific Reports
PDF
1123 TNFR1 expression on cancer cells is critical for immune escape shaping an immunosuppressive tumor microenvironment
2026
·
Lorena Cañas Zabala
, Elixabet Bolaños
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
CD137 agonists in mice suppress germinal center responses by increasing the immunosuppressive activity of follicular regulatory T-cells
2026
·
Ana Martínez-Riaño
, Raquel Cuesta
, et al.
·
The EMBO Journal
PDF
Figure S5 from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026
·
Miguel F. Sanmamed
, Carlos E. de Andrea
, et al.
Table S3 from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026
·
Miguel F. Sanmamed
, Carlos E. de Andrea
, et al.
Table S2 from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026
·
Miguel F. Sanmamed
, Carlos E. de Andrea
, et al.
Figure S2 from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026
·
Miguel F. Sanmamed
, Carlos E. de Andrea
, et al.
Table S4 from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026
·
Miguel F. Sanmamed
, Carlos E. de Andrea
, et al.
Figure S1 from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026
·
Miguel F. Sanmamed
, Carlos E. de Andrea
, et al.
Data from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026
·
Miguel F. Sanmamed
, Carlos E. de Andrea
, et al.
Figure S3 from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026
·
Miguel F. Sanmamed
, Carlos E. de Andrea
, et al.
Supplementary Appendix from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026
·
Miguel F. Sanmamed
, Carlos E. de Andrea
, et al.
Table S1 from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026
·
Miguel F. Sanmamed
, Carlos E. de Andrea
, et al.
Figure S4 from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026
·
Miguel F. Sanmamed
, Carlos E. de Andrea
, et al.
531 A multi-cohort phase 1-2 clinical trial shows safety, feasibility and pharmacodynamic activity of intratumoral injections of the agonist anti-CD137 (4–1BB) mAb urelumab in combination with nivolumab
2025
·
Miguel F Sanmamed
, Carlos E De Andrea
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
Show more works
View as search
Works count:
23
Citation count:
40
H-index:
5
I10-index:
1
Year
Topic
Type